Board of Directors | 60 Degrees Pharmaceuticals, Inc.

Geoffrey Dow is the CEO, President, and a Director of 60 Degrees Pharmaceuticals, Inc. (60P). He has over 20 years of experience in product development for tropical diseases and a strong publication and patent history. He has 13 years of leadership and advisory experience in the antimalarial drug development program at the Walter Reed Army Institute of Research and the U.S. Army Medical Materiel Development Activity. Dr. Dow co-founded 60P in 2010 and has been instrumental in various projects including securing FDA-regulatory approval for tafenoquine (Arakoda) for malaria prophylaxis, managing post-marketing regulatory commitments, and ensuring the company adheres to GMP, quality, and pharmacovigilance requirements. He has also published several important safety reviews, clinical trials, and non-clinical studies. Dr. Dow's ultimate goal is to develop and secure regulatory approval and commercial success of products for new indications in infectious disease. He holds a B.Sc. (Hons) in Veterinary and Biomedical Science from Murdoch University, Perth, Western Australia (1994), a Ph.D. in Veterinary and Biomedical Science from Murdoch University (2000), and an MBA from the University of Maryland at College Park (2012).

Charles Allen is a member of the board of 60 Degrees Pharmaceuticals, Inc. (60P) and has served as CEO of BTCS Inc. since February 5, 2014 and as Chairman of BTCS since September 11, 2014. He is responsible for BTCS' overall corporate strategy and direction. He also serves as a director of Innovation1 Biotech Inc. since December 5, 2022. He has extensive experience in business strategy, investment banking and capital markets transactions, such as financings, initial public offerings, and mergers and acquisitions. He has served as a managing director at various boutique investment banks and has worked domestically and internationally on projects in technology, media, natural resources, logistics, medical services, and financial services. He holds a Bachelor of Science in Mechanical Engineering from Lehigh University and a Master of Business Administration from the Mason School of Business at the College of William & Mary.

Cheryl Xu is a director who currently serves as Biogen's VP of Public Policy & Government Affairs. Previously, she ran a consulting business advising multinational companies on market access and expansion in China. She has also provided consultations to the US and Chinese governments on pharmaceutical policies, and was the Director of International Finance at Pharmacia. She holds a B.S. in Physics from Peking University and an MBA in Finance from Washington University.

Dr. Stephen Toovey is a director who is an infectious and tropical disease physician. He has experience in the pharmaceutical industry and academia in both developed and developing countries. He currently specializes in the research of influenza and other respiratory viruses, malaria, rabies and the neurological aspects of infectious diseases. He is CEO of Pegasus, a medical and scientific services company, and advises pharmaceutical companies and biotech organizations on infection related matters. He has founded several pharmaceutical and pharma-related companies, including co-founding Ark Biosciences in 2014 and served as its CMO until 2020. He previously taught at the Royal Free, continues to teach at University College Medical School and is deputy editor of the journal Travel Medicine and Infectious Disease. He has authored over 100 publications and presented at over 50 scientific meetings, and holds a PhD from the University of Ghent. The Board believes his background and leadership experiences in the pharmaceutical industry and academia qualify him for the role of director.

Paul Field is a director with over 30 years of business development experience in the biopharmaceutical industry across a range of therapeutic areas. He is currently a corporate advisor at several companies, including Imunexus Ltd. and the Global Antibiotic R&D Partnership (Geneva). Previously, he was the life sciences specialist at the Australian government agency Austrade, where he facilitated foreign investment in Australian research on neglected tropical diseases, autoimmune diseases, cancer, and other programs. He has served on multiple boards of directors and is a Fellow of the Australian Institute of Company Directors

Eric Francois is a life sciences executive with over 25 years of experience, including 18 years as a senior banker with Raymond James, Credit Suisse, Lazard, and Cowen. He previously served as CFO and CBO of SCYNEXIS, a publicly traded anti-infectives company, where he raised over $300M and led business development activities. He also served as a director at Diffusion Pharma during its merger with EIP Pharma to form CervoMed. Mr Francois currently serves as a board member of CERo Therapeutics, an immunotherapy oncology company, providing strategic guidance on capital structure, business development, and transactions. He earned his MA in business and marketing from the Sorbonne University in France, where he also earned his BA in economics and business administration.